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The 9p21.3 risk of childhood 
acute lymphoblastic leukaemia is 
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Jayaram Vijayakrishnan1, Marc Henrion1, Anthony V. Moorman4, Bettina Fiege2, 
Rajiv Kumar2, Miguel Inacio da Silva Filho2, Amy Holroyd1, Rolf Koehler3, Hauke Thomsen2, 
Julie A. Irving4, James M. Allan4, Tracy Lightfoot5, Eve Roman5, Sally E. Kinsey6,7, 
Eamonn Sheridan7, Pamela D. Thompson8, Per Hoffmann9,16, Markus M. Nöthen9,17, 
Thomas W. Mühleisen9, Lewin Eisele11, Claus R. Bartram3, Martin Schrappe13, 
Mel Greaves14, Kari Hemminki2,15, Christine J. Harrison4, Martin Stanulla13 & 
Richard S. Houlston1
Genome-wide association studies (GWAS) have provided strong evidence for inherited predisposition 
to childhood acute lymphoblastic leukaemia (ALL) identifying a number of risk loci. We have 
previously shown common SNPs at 9p21.3 influence ALL risk. These SNP associations are generally 
not themselves candidates for causality, but simply act as markers for functional variants. By means 
of imputation of GWAS data and subsequent validation SNP genotyping totalling 2,177 ALL cases 
and 8,240 controls, we have shown that the 9p21.3 association can be ascribed to the rare high-
impact CDKN2A p.Ala148Thr variant (rs3731249; Odds ratio = 2.42, P = 3.45 × 10−19). The association 
between rs3731249 genotype and risk was not specific to particular subtype of B-cell ALL. The 
rs3731249 variant is associated with predominant nuclear localisation of the CDKN2A transcript 
suggesting the functional effect of p.Ala148Thr on ALL risk may be through compromised ability to 
inhibit cyclin D within the cytoplasm.
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Acute lymphoblastic leukaemia (ALL) is the major paediatric cancer in western countries, with B-cell 
precursor (BCP) ALL accounting for ~80% of cases1. To date the aetiology of ALL is poorly understood 
and while there is indirect evidence for an infective origin, no specific environmental risk factors have 
been identified. Evidence for inherited predisposition to ALL is provided by the increased risk seen in 
siblings of cases independent of the concordance in monozygotic twins, which has an in utero basis2.
By performing a genome-wide association study (GWAS) we have previously shown common SNPs at 
9p21.3 annotating CDKN2A/CDKN2B influences ALL risk3. The tagSNPs associations discovered in such 
GWAS are however rarely themselves candidates for causality, but simply act as markers for functional 
variants.
To decipher the association signal at 9p21.3 we performed imputation of two GWAS datasets and 
subsequent replication SNP genotyping. Our analysis demonstrates that the 9p21.3 association for ALL 
can be ascribed to a rare high-impact haplotype at 9p21.3 which captures a CDKN2A exon 2 variant.
Results
Using Haploview we defined the haplotype blocks and recombination hotspots containing the tag sen-
tinel SNP rs3731217 (hg19 chr9:g.21984661 A > C) previously found to be associated with ALL risk 
at 9p21.3. rs3731217 is contained within an 174-kb LD block (at hg19 chr9:g.21,942,000–22,116,000 
base pairs [bp]) and to include the possibility of long-range synthetic associations, we considered the 
9q21.3 region of association to be defined by a 400kb interval (rs10965124, hg19 chr9:g.21776615 T> G 
to rs117009334, hg19 chr9:g.22176265 C > T). To fine map the 9p21.3 risk locus we made use of data 
from two previously published GWAS - (i) The German GWAS comprising 1155 B-cell ALL cases ascer-
tained through the German Berlin-Frankfurt-Munster (BFM) group childhood ALL trials and 2125 
controls from the Heinz-Nixdorf Recall (HNR) study; (ii) the UK GWAS comprising 824 B-cell cases 
from United Kingdom Childhood Cancer Study (UKCCS), UK MRC ALL 97 trial (http://www.thelancet.
com/protocol-reviews/97PRT-14) and Northern Institute for Cancer Research; 5,200 controls from the 
1958BC and UK Blood donors (http://www.cls.ioe.ac.uk/). After QC the two GWAS provided genotype 
data on 1,658 B-cell ALL cases (824 UKGWAS and 834 German-GWAS samples) and 7,224 controls 
in total. To harmonise GWAS datasets and recover untyped SNPs we made use of imputation using 
1000Genomes and UK10K (http://www.uk10k.org/) as reference panels thereby allowing for the com-
prehensive examination of SNPs with minor allele frequency (MAF) > 0.005 in the genomic region with 
IMPUTE2 software (https://mathgen.stats.ox.ac.uk/impute/impute).
Pooling data from each GWAS, we derived joint ORs and 95% confidence intervals (CIs) under a 
fixed-effects model for each SNP and the associated per-allele P values. The strongest association at 9p21.3 
in each GWAS and in the meta-analysis were provided by the rare SNPs rs3731249 (hg19 chr9:g.21970916 
G > A), rs36228834 (hg19 chr9:g.21975319 T > A) and rs113650570 (hg19 chr9:g.21976402 G > A) (MAF 
in cases 0.05–0.08); with combined P-values of 6.03 × 10−16, 4.15 × 10−16 and 3.88× 10−16 respectively 
(Supplementary Table 1, Fig.  1), which was far more significant than the association provided by the 
sentinel GWAS SNP rs3731217 (Pcombined = 1.52 × 10−8, Supplementary Table 3). We validated rs3731249, 
rs113650570 and rs36228834 genotypes by sequencing 93 samples from the UK series; samples showing 
100% concordance.
For replication we genotyped an additional 519 B-cell ALL cases from the UK ALL2003 trial and 
1,016 population controls from the National Study of Colorectal Cancer Genetics (NSCCG) study4. 
This analysis provided increased evidence for an association between SNPs rs3731249, rs113650570 and 
rs36228834 and risk of ALL (Table 1). Pooling genotype data for all of three series provided unequivo-
cal evidence for a relationship between rs3731249 (P = 3.45× 10−19), rs36228834 (P = 4.41 × 10−19) and 
rs113650570 (P = 9.21 × 10−19) and ALL risk. There was no evidence for between study heterogeneity 
and combined odds ratios (OR) and 95% confidence intervals (95% CI) were 2.42 (95% CI: 1.99–2.93), 
2.41 (95% CI: 1.99–2.92) and 2.39 (95% CI: 1.97–2.89) respectively (Table 1). Additionally there was no 
evidence that one of the series had significantly biased study findings - for rs3731249 the P-values for 
Begg’s and Egger’s tests were 1.00 and 0.35 respectively.
The SNPs rs3731249, rs113650570 and rs36228834 are in linkage disequilibrium (LD) - pairwise D’ 
and r2 metrics between rs113650570 and rs36228834, 1 and 0.99; between rs113650570 and rs3731249, 
0.99 and 0.98; between rs36228834 and rs3731249, 0.99 and 0.98 respectively. Hence, while the strongest 
association was provided by rs3731249 the three SNPs collectively define a single risk haplotype.
To examine the possibility that the haplotype association might capture additional coding changes 
in CDKN2A, we sequenced all exons of CDKN2A/CDKN2B in 93 of the UK GWAS cases which were 
carriers of the risk haplotype. Only one additional coding change in CDKN2A was identified, a heterozy-
gous deletion of G within the 3′ UTR of NM 001195132 (hg19 chr9:g.21968623G> _). Collectively these 
data make it unlikely that the haplotype association is a consequence of association through a sequence 
change other than rs3731249, rs113650570 or rs36228834.
rs113650570 and rs36228834 are both non-coding SNPs which localise to intron 1 of CDKN2A-p14ARF 
(NM_058195.3). Neither of the SNPs reside within strong evolutionary conserved domains (GERP and 
PhastCon scores – 0.67, 0.22 and 3.44, 0.05 respectively; Fig. 1) and the genomic regions do not exhibit 
regulatory function as defined by histone markers or transcription factor binding. rs3731249 is responsi-
ble for the exon 2 p.Ala148Thr change in the CDKN2A protein transcripts p16INK4a (NP_000068; NCBI, 
http://www.ncbi.nlm.nih.gov/) and predicted protein transcript cdkn2a isoform X3 (XP_005251400.1; 
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NCBI). While the genomic position to which rs3731249 maps is not evolutionarily conserved (GERP 
and PhastCon scores 1.06 and 0.00 respectively), protein modelling using SuSPect5 software implies that 
the p.Ala148Thr change is unlikely to be neutral and rs3731249 is predicted to be possibly damaging by 
PolyPhen (PolyPhen2 score = 0.49, protein accession: P42771- CD2A1_HUMAN). Direct evidence for 
rs3731249 being functional is provided by transfection studies6.
To explore the possibility that somatic loss of the wild-type allele preferentially occurs in the leukemic 
clones of rs3731249 carriers we examined the relationship between genotype carrier status and CDKN2A 
and CDKN2B deletion in the leukaemic clones of 43 UKGWAS B-cell and 519 replication series B-cell 
Figure 1. Regional plots of association results and recombination rates for the 9p21.3 risk locus. The top 
panel shows the association results of both genotyped (triangles) and imputed (circles) SNPs in the GWAS 
samples and recombination rates for rates within the two loci. For each plot, − log10 P values (y-axis) of the 
SNPs are shown according to their chromosomal positions (x-axis). The top SNP in the combined analysis 
is a large circle and is labelled by its reference SNP ID. The color intensity of each symbol reflects the extent 
of LD with the top genotyped SNP: white (r2 = 0) through to dark red (r2 = 1.0). Genetic recombination rates 
(cM/Mb), estimated using HapMap CEU samples, are shown with a light blue line. Physical positions are 
based on National Centre for Biotechnology Information build 36 of the human genome. Also shown are the 
relative positions of genes and transcripts mapping to each region of association. Genes have been redrawn 
to show the relative positions; therefore, maps are not to physical scale. The lower panel shows the gene of 
interest together with all transcripts of the gene showing exons and introns; observed SNP and any imputed 
SNPs showing a stronger association with ALL risk, chromatin state segmentation track (ChromHMM), and 
phastCons score values corresponding to the posterior probability associated with a phylogenetic hidden 
Markov model (HMM) inferring the most conserved state at a given base position. *chromHMM colour 
codes: Bright Red - active promoter; Light Red - Promoter Flanking; Purple - Inactive Promoter; Orange - 
Candidate Strong enhancer; Yellow - Candidate Weak enhancer; Blue - Distal CTCF/Candidate Insulator; 
Dark Green - Transcription associated; Light Green - Low activity proximal to active states; Gray - Polycomb 
repressed; Light Gray - Heterochromatin/Repetitive/Copy Number Variation.
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cases (Table  2). There was, however, no evidence for a relationship between rs3731249 genotype and 
CDKN2A deletion (P = 0.59).
The association between 10q21.2 and 10p14 and risk of BCP-ALL are highly subtype specific5. To 
investigate the relationship between variation in 9p21.3 and ALL further we conducted a stratified anal-
ysis using data on 137 ETV6-RUNX1 and 169 B-high hyperdiploid cases and rs3731249. In this analysis 
there was no evidence that the influence of rs3731249 genotype on ALL risk is subtype specific (Table 3).
Discussion
Here we have provided evidence that the 9p21.3 association for risk of ALL can be ascribed to a recur-
rent rare high impact variant in CDKN2A. CDKN2A encodes both p16 (INK4A), a negative regulator of 
cyclin-dependant kinases, and p14 (ARF1), an activator of p53. CDKN2A and CDKN2B are inactivated 
in a number of different cancers, and mono- or biallelic deletion of CDKN2A are recurrent events in 
childhood ALL7. CDKN2A deletions are generally considered to arise as secondary events and cooper-
ate with the initiating abnormality such as ETV6-RUNX1 fusions to drive disease. CDKN2A/CDKN2B 
deletions occur in approximately 30% of childhood ALL but are often acquired at relapse where the 
frequency is 40%8–10.
The p.Ala148Thr variant is located towards C-terminus of the p16INK4A and is thus not within 
ankyrin repeats11 (Supplementary Figure 1) through which p16INK4A binds with CDK4. In functional 
SNP
RAFa
ORb (95% CIc) P-valueCases Controls
rs3731249 
 UK GWAS 0.05 0.03 2.48 (1.77–3.48) 1.22 × 10−07
 German GWAS 0.08 0.03 2.46 (1.84–3.28) 9.42 × 10−10
 Replication 0.05 0.02 2.24 (1.48–3.39) 1.40 × 10−04
 Combined 2.42 (1.99–2.93) 3.45 × 10−19
Phet = 0.92, I2 = 0%
rs36228834
 UK GWAS 0.05 0.03 2.52 (1.80–3.52) 6.22 × 10−08
 German GWAS 0.08 0.03 2.44 (1.83–3.26) 1.25 × 10−09
 Replication 0.05 0.02 2.19 (1.45–3.30) 1.90 × 10−04
 Combined 2.41 (1.99–2.92) 4.41 × 10−19
Phet = 0.86, I2 = 0%
rs113650570
 UK GWAS 0.05 0.03 2.52 (1.80–3.52) 6.05 × 10−08
 German GWAS 0.08 0.03 2.44 (1.83–3.26) 1.20 × 10−09
 Replication 0.05 0.02 2.09 (1.39–3.16) 4.10 × 10−04
 Combined 2.39 (1.97–2.89) 9.21 × 10−19
Phet = 0.77, I2 = 0%
Table 1.  Association between rs3731249, rs113650570 and rs36228834 genotypes and risk of developing 
B-cell childhood acute lymphoblastic leukaemia. aRisk allele frequency (RAF). bOdds ratio. c95% 
Confidence Interval.
Study
rs3731249 risk allele 
status
CDKN2A deletion status
P-valueNot deleted Deleted
UK GWAS
Carriera 4 1
1.0
Non-carrierb 30 8
Replication
Carriera 36 11
0.57
Non-carrierb 378 94
Combined P-value 0.59
Table 2.  Relationship between rs3731249 risk allele and CDKN2A deletion in childhood B-cell ALL. 
aSamples that are a carrier of rs3731249 risk allele T. bsamples that are non-carriers of rs3731249 risk  
allele T.
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studies while the variant protein has been shown to bind to CDK4 and CDK6 6 it has shown to be asso-
ciated with predominant nuclear localisation of CDKN2A transcript. This is consistent with the func-
tional effect of rs3731249 on ALL risk being through compromised ability to inhibit cyclin D within 
the cytoplasm6. Although a slightly higher colony count than the wild type protein has been reported 
in association with rs3731249, providing an indication of a subtle effect on inhibitory capabilities, the 
effect was not statistically significant and hence at this juncture the observation needs to with interpreted 
with caution.
While we found no evidence for a relationship between rs3731249 genotype and CDKN2A deletion 
this does not of course preclude the possibility that the genotype might be associated with allelic imbal-
ances within a subclone. Indeed subclonal heterogeneity in CDKN2A copy number was evident in these 
data (Supplementary Figure 2) consistent with the published assertion that CDKN2A alterations are 
secondary events in leukaemogenesis8.
In conclusion, we have been able to demonstrate that the 9p21 association for ALL can be ascribed 
to a rare high impact variant. Given that variation at 9p21.3 has been implicated in risk of other malig-
nancies we assessed the effect of rs3731249 on risk of other cancers with known chr9p21.3 GWAS asso-
ciations but observed no association between the variant and either glioma (glioblastoma and non-GBM 
cancers), colorectal, lung cancer or melanoma (MelGeneDB, http://www.melgene.org) suggesting an 
ALL-specific role for rs373124912–15. Further studies are required to determine the precise biological 
basis of the association. Finally our data also provide an important proof of principle that imputation 
based on large reference panels such as the UK10K can be used to detect novel, low frequency-large effect 
associations, thereby extending the utility of pre-existing GWAS data.
Methods
Ethics. Collection of samples and clinico-pathological information from subjects was undertaken with 
informed consent in accordance with the Declaration of Helsinki and ethical board approval. Ethical 
committee approval was obtained for Medical Research Council UKALL97/99 trial by individual UK 
treatment centres and approval for UKALL2003 was obtained from the Scottish Multi-Centre Research 
Ethics Committee (REC:02/10/052). Additional ethical approval was obtained under the auspices of 
the Childhood Leukaemia Cell Bank, the United Kingdom Childhood Cancer Study and University of 
Heidelberg16.
Genome-wide association study. The United Kingdom (UK)-GWAS and German-GWAS have been 
previously reported3,17. Briefly, the UK-GWAS was based on constitutional DNA (i.e. remission samples) 
of 459 white BCP-ALL cases from the United Kingdom Childhood Cancer Study (UKCCS; http://www.
ukccs.org/; 258 male; mean age at diagnosis 5.3 years); 342 cases from the UK Medical Research Council 
(MRC) ALL 97/99 (1997–2002) trial (190 male; mean age of diagnosis 5.7 years) and 23 cases from 
Northern Institute for Cancer Research (16 males). Genotyping was performed using Illumina Human 
317K arrays (Illumina, San Diego; Available at: http://www.illumina.com). For controls we used publicly 
accessible data generated by the Wellcome Trust Case Control Consortium 2 (http://www.wtccc.org.
uk/) from 2,699 individuals in the 1958 British Birth Cohort (Hap1.2M-Duo Custom array data) and 
2,501 individuals from the UK Blood Service. The German GWAS was comprised of 1,155 cases (620 
male; mean age at diagnosis 6.0 years) ascertained through the Berlin-Frankfurt-Münster (BFM) trials 
(1993–2004) genotyped using Illumina Human OmniExpress-12v1.0 arrays. For controls we used gen-
otype data from 2,132 healthy individuals from the Heinz Nixdorf Recall (HNR) study; consisting of 
704 individuals genotyped using Illumina-HumanOmni1-Quad_v1 and 1,428 individuals genotyped on 
Illumina-HumanOmniExpress-12v1.0 platform to obtain a final of 2024 individuals after quality control.
Quality control of GWAS datasets. DNA samples with GenCall scores < 0.25 at any locus were 
considered “no calls”. Any SNP was deemed to have failed if < 95% of DNA samples generated a genotype 
at the locus. Cluster plots were manually inspected for SNPs considered for replication. The same quality 
control metrics on the German GWAS data were applied as in the UK GWAS. We removed individuals 
aged > 16 years (n = 10); sex discrepancy issues (n = 2) and samples for whom < 95% of SNPs were 
successfully genotyped (n = 5) (supplemental Fig. 1). We computed identity-by-state (IBS) probabili-
ties for all pairs to search for duplicates and closely related individuals among samples (defined as IBS 
≥ 0.80, thereby excluding first-degree relatives). For all identical pairs the sample having the highest call 
ALL Subtype
rs3731249 genotypes (CC/CT/TT)
RAFa in controls P-valuedCases
ETV6-RUNX1 122/14/1 0.02 0.78
Hyperdiploid 153/16/0 0.02 –
Table 3.  Relationship between rs3731249 and risk of developing ALL subtypes. aRAF: risk allele 
frequency. bOR: odds ratio and cCI: confidence intervals. dP-value from stratified analysis.
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rate was retained, thereby eliminating 3 samples. To identify individuals who might have non-Western 
European ancestry, we merged our data with phase II HapMap (http://www.hapmap.org) samples (60 
Western European [CEU], 60 Nigerian [YRI], 90 Japanese [JPT] and 90 Han Chinese [CHB]). For each 
pair of individuals, we calculated genome-wide IBS distances on markers shared between HapMap and 
our SNP panel, and we used these as dissimilarity measures on which to perform principal component 
analysis. The first 2 principal components for each individual were plotted, and 37 samples showing 
marked separation from the CEU cluster was excluded from the analyses. Due to the spread of the case 
cluster we then performed an additional principal component analysis step making use of phase III 
HapMap samples (111 CEU, 88 Toscans in Italy [TSI] individuals), and we removed a further 265 cases 
and 9 controls not present in the main cluster. We filtered out SNPs having a minor allele frequency 
of < 1%, and a call rate of < 95% in cases or controls. We also excluded SNPs showing departure from 
Hardy-Weinberg equilibrium at P < 10−6.
Replication series and genotyping. The replication series comprised of 519 patients (297 male; 
mean age at diagnosis: 6.2 years) ascertained through the UK Medical Research Council ALL 2003 
(2003–2011) trial. Immunophenotyping of diagnostic samples was undertaken using standard methods. 
The 1,016 controls (283 males) were ethnically-matched healthy individuals with no personal history of 
cancer recruited to the National Study of Colorectal Cancer Genetics (NSCCG)4. DNA was extracted 
from cell pellets using standard phenol-choloform methods. Genotyping of cases and controls was per-
formed using competitive allele-specific polymerase chain reaction KASP chemistry (LCG Biosciences 
Ltd., Hertfordshire, UK). Samples having SNP call rates of < 90% were excluded from the analysis. To 
ensure quality of genotyping in all assays, at least 2 negative controls and 1% to 2% duplicates (concord-
ance > 99.99%) were genotyped.
Sanger sequencing. Samples were sequenced using BigDye® Terminator v3.1 Cycle Sequencing Kit 
(Life Technologies) using oligonucleotides mentioned in Supplementary Table 2.
Statistical and bioinformatic analysis. Main analyses were undertaken using R (v2.6; R Core 
Team (2013), a language and environment for statistical computing (http://www.R-project.org/), PLINK 
(v1.06)18 and SNPTEST (v2.4.1)19 software. The association between each SNP and risk was assessed by 
the Cochran-Armitage trend test. ORs and associated 95% CIs were calculated by unconditional logistic 
regression. The adequacy of case-control matching and possibility of differential genotyping of cases 
and controls were formally evaluated using quantile-quantile plots of test statistics. The inflation factor 
λ was based on the 90% least significant SNPs20. We adjusted for possible population substructure using 
Eigenstrat21. Prediction of the untyped SNPs was carried out using IMPUTEv2 (v2.3.0) based on the data 
from the 1000 Genomes Project (Phase 1 integrated variant set, v3.20101123, http://www.1000genomes.
org, 9 December 2013) and UK10K (ALSPAC, EGAS00001000090/EGAD00001000195, and TwinsUK, 
EGAS00001000108/EGAD00001000194, studies only; http://www.uk10k.org/) as reference. Imputed 
data were analyzed using SNPTEST v2.4.1 to account for uncertainties in SNP prediction. Association 
meta-analyses only included markers with info scores > 0.4, imputed call rates/SNP > 0.9 and MAFs 
> 0.005. Meta-analyses were carried out with the R package meta v2.4-1, using the genotype probabili-
ties from IMPUTEv2, where a SNP was not directly typed. To filter poorly imputed SNPs we excluded 
variants with information scores from SNPTEST v2.3.0 < 0.4. We calculated Cochran’s Q statistic to test 
for heterogeneity and the I2 statistic to quantify the proportion of the total variation that was caused 
by heterogeneity22. The presence of bias was formally evaluated with Begg’s adjusted rank correlation 
test and Egger’s regression asymmetry test23. Test of proportions was performed using Fishers exact test 
(2-sided) using STATA software (StataCorp. 2007. Stata Statistical Software: Release 10. College Station, 
TX: StataCorp LP).
Linkage disequilibrium (LD) metrics were calculated in PLINK18 using UK10K genomic data. 
LD blocks were defined on the basis of HapMap recombination rate, as defined by using the Oxford 
recombination hotspots, and on the basis of distribution of CIs24,25. Prediction of the effects of mis-
sence changes was performed using POLYPHEN. Genomic evolutionary rate profiling (GERP)26 and 
PhastCons27 scores were used to assess sequence conservation. SuSPect software (http://www.sbg.bio.
ic.ac.uk/suspect/) was used to explore any deleterious effect of coding variant on protein function and 
structure5. The association and features plots were constructed using visPIG sofware28 (www.vispig.icr.
ac.uk). To explore epigenetic profile of association signals, we used chromatin state segmentation data 
learned by computationally integrating Chip-seq data inferred from ENCODE Histone Modification 
data (H4K20me1, H3K9ac, H3K4me3, H3K4me2, H3K4me1, H3K36me3, H3K27me3, H3K27ac, and 
CTCF) and binarized using a multivariate Hidden Markov Model29 (http://genome.ucsc.edu/ENCODE/). 
We used RegulomeDB and HaploReg to examine if any of the SNPs annotate putative transcription fac-
tor binding/enhancer elements. cBioPortal (http://www.cbioportal.org) was used to explore the protein 
structure of the variant explored11.
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9p21.3 (CDKN2A) copy number analysis in ALL. To study the relationship between SNP genotype 
and 9p21.3 monoallelic/biallelic deletion in tumours we analysed data on NCRI CCLG ALL2003 trial 
samples cases. Genomic copy number at 9p21.3 was assayed in diagnostic tumour samples using FISH 
and MLPA as previously described7,8.
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